TNFRSF17(BCMA) Chimeric Antigen Receptor (CAR): A Comprehensive Guide and Our Service & Product Introduction

BCMA (B-cell Maturation Antigen) is a protein that is almost universally expressed on the surface of plasma cells and multiple myeloma cells. Due to its highly selective expression on malignant cells (and not on essential non-blood tissues), it serves as an ideal biomarker and therapeutic target for multiple myeloma.

RGBiotech’s BCMA CAR expression plasmids and custom services are designed to accelerate your immunotherapy research workflow, reduce experimental variability, and support breakthrough discoveries in multiple myeloma and B-cell malignancy treatment. With high-quality reagents, flexible customization, and strict quality control, we are your trusted partner for BCMA-targeted CAR research.

Our TNFRSF17(BCMA) CAR Expression Plasmid Vector Products and Custom Services

RGBiotech offers a full spectrum of high-quality TNFRSF17 (BCMA) CAR expression plasmid vectors covering different CAR generations, plus flexible custom plasmid construction services to support research. Our products are engineered for high expression efficiency, stable inheritance, and compatibility with multiple delivery systems.

Our catalog includes BCMA CAR plasmids spanning multiple generations, with customizable co-stimulatory domains (CD28, 4-1BB, OX40, ICOS) to match diverse research objectives. We provide BCMA CAR plasmids with multiple backbone systems to suit different research models and delivery methods:
1) Lentiviral vectors: Production of lentiviral particles, high transduction efficiency in both dividing and non-dividing cells, stable long-term expression, ideal for primary T-cell/NK cell engineering.
2) Retroviral vectors: Production of retroviral particles, efficient integration and stable expression in dividing immune cells, widely used in traditional CAR-T manufacturing.
3) AAV vectors: Production of AAV particles, non-integrating, low immunogenicity, suitable for in vivo delivery and long-term transient expression; multiple serotypes available.
4) Non-viral plasmid vectors: Safe, cost-effective, easy to amplify and modify; ideal for in vitro cell line engineering, transient expression, and preliminary screening.

Product Features & Advantages

Product Applications

Custom BCMA CAR Plasmid Construction Service

We offer tailored custom BCMA CAR plasmid design and construction services to meet unique research needs:
1) Custom scFv cloning (customer-provided anti-BCMA antibodies)
2) Custom co-stimulatory domain combinations and CAR generation optimization
Addition of therapeutic cytokines, checkpoint inhibitors, or other functional modules
3) Dual-target CAR plasmid construction (BCMA + other tumor antigens)
4) Vector backbone modification and promoter selection
5) Full-length DNA sequencing verification of entire CAR insert and large scale plasmid preparation

Introduction of TNFRSF17 (BCMA)

TNFRSF17, also commonly known as B-cell Maturation Antigen (BCMA), is a protein-coding gene located on human chromosome 16p13.13. It belongs to the tumor necrosis factor receptor (TNFR) superfamily, a critical family of immune regulatory receptors governing cell survival, proliferation, and apoptosis. The gene encodes a type I transmembrane glycoprotein with a relatively conserved open reading frame, and its expression is tightly restricted to specific B-cell lineage cells, making it a highly specific target for B-cell-related malignancies and immunotherapy research.

The full-length BCMA protein consists of approximately 184 amino acids, with a classic three-domain structure typical of TNFR family members:
1) Extracellular domain (ECD): Contains a conserved cysteine-rich domain (CRD), which is the core binding region for its natural ligands, including B-cell activating factor (BAFF, TNFSF13B) and a proliferation-inducing ligand (APRIL, TNFSF13). This domain is the target site for BCMA-targeted CAR single-chain variable fragments (scFv).
2) Transmembrane domain (TMD): A hydrophobic alpha-helical domain that anchors the protein to the cell membrane, ensuring stable surface expression.
3) Intracellular cytoplasmic domain: Mediates downstream intracellular signaling, primarily activating the NF-κB and JNK signaling pathways to regulate cell survival and immune responses.

BCMA is a key regulator of B-cell homeostasis and humoral immunity, with non-redundant physiological roles:
1) Promotes the survival, maturation, and long-term maintenance of plasma cells and mature memory B cells, supporting durable antibody production.
2) Mediates ligand-induced signaling to balance B-cell proliferation and apoptosis, preventing abnormal B-cell expansion.
3) Plays a vital role in adaptive immune responses, particularly in secondary lymphoid organs and bone marrow microenvironments.

BCMA exhibits highly restricted tissue expression, a feature that underpins its exceptional safety and specificity as an immunotherapy target:
1) Strongly expressed on malignant plasma cells in multiple myeloma (MM), the vast majority of MM cell lines, and primary MM patient samples.
2) Specifically expressed on mature B cells, memory B cells, and long-lived plasma cells in normal physiological conditions.
3) Negligible or absent expression on hematopoietic stem cells, other normal somatic tissues, and non-B-cell lineage immune cells, minimizing off-target effects in targeted therapy.

BCMA is most prominently linked to B-cell malignancies, especially incurable hematological cancers, and is also implicated in certain autoimmune disorders:
1) Multiple Myeloma (MM): The most clinically relevant indication; BCMA is uniformly and highly expressed on MM cells, making it the gold-standard target for MM immunotherapy, including CAR-T, bispecific antibodies, and antibody-drug conjugates (ADCs).
2) Other B-cell malignancies: Non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and other plasma cell dyscrasias.
3) Autoimmune diseases: Systemic lupus erythematosus (SLE), rheumatoid arthritis, and myasthenia gravis, where abnormal B-cell and plasma cell activation drives pathogenic antibody production.

Introduction of TNFRSF17 (BCMA) Chimeric Antigen Receptor (CAR)

BCMA CAR is a genetically engineered chimeric antigen receptor designed to specifically target BCMA-expressing cells. It redirects T-cell cytotoxicity to eliminate BCMA-positive malignant cells independently of MHC restriction, a breakthrough in adoptive cell immunotherapy. A typical BCMA CAR construct consists of four core modules:
1) Antigen-binding domain: Usually an anti-BCMA scFv fragment, responsible for specific recognition of BCMA protein on target cells.
2) Hinge/transmembrane region: Connects the extracellular and intracellular domains, ensuring structural stability and signal transmission.
3) Intracellular co-stimulatory domain(s): Determines CAR-T cell activation, proliferation, persistence, and cytotoxic efficacy (varies by CAR generation).
4) Activation signaling domain: Typically CD3ζ chain, the primary driver of T-cell cytotoxic function and immune synapse formation.

BCMA CAR designs have evolved across multiple generations to enhance efficacy, safety, and persistence, with distinct structural and functional differences:
1) 1st Generation BCMA CAR: Contains only CD3ζ activation domain, no co-stimulatory domains. Limited T-cell persistence and cytotoxicity, minimal clinical application, mainly used for in vitro preliminary research.
2) 2nd Generation BCMA CAR: Combines CD3ζ with one co-stimulatory domain (most commonly CD28 or 4-1BB). Significantly improves T-cell activation, proliferation, and in vivo persistence; all FDA/EMA/NMPA approved BCMA CAR-T products are 2nd generation, the current clinical gold standard.
3) 3rd Generation BCMA CAR: Integrates two co-stimulatory domains (e.g., CD28 + 4-1BB, CD28 + OX40). Enhances signaling strength and cytotoxicity but may increase risk of cytokine release syndrome (CRS); used in advanced preclinical and early clinical studies.
4) 4th Generation BCMA CAR (Armored/TRUCK CAR): Equipped with additional functional elements, such as inducible cytokine secretion (IL-12, IL-15), immune checkpoint inhibitors (PD-1/PD-L1 blockers), or chemokine receptors. Overcomes tumor microenvironment (TME) suppression, boosts anti-tumor activity, and reduces T-cell exhaustion; a major research hotspot for next-generation BCMA CAR-T.

Approved BCMA CAR-T Therapeutics (Clinical Milestones)

BCMA CAR-T has revolutionized the treatment of relapsed/refractory multiple myeloma (R/R MM), with several landmark products approved globally:
1) Idecabtagene vicleucel (Abecma®, Bristol Myers Squibb/Bluebird Bio): First FDA-approved BCMA CAR-T (2021), indicated for R/R MM after ≥4 prior lines of therapy; demonstrated robust objective response rates (ORR) and durable remission in clinical trials.
2) Ciltacabtagene autoleucel (Carvykti®, Janssen/Legend Biotech): FDA-approved in 2022, a second-generation BCMA CAR-T with dual-target scFv design; shows high efficacy in heavily pretreated R/R MM patients, including those with high-risk disease features.
3) Ikinacabtagene autoleucel (Fukesu®, Innovent Biologics/IASO Biotech): First domestically developed BCMA CAR-T approved by NMPA (2023), for R/R MM in adult patients, filling the gap of domestic BCMA CAR-T therapy.

Current Research Hotspots of BCMA CAR

Research Challenges & Limitations

References

Contact Us